Clone:
REA414
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC, ICC
Alternative names:
CEACAM6, CEAL, NCA, NCA-90

Extended validation for CD66c Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA414
B6.2/CD66++
KOR-SA3544++
REA428+
Cells were incubated with an excess of purified unconjugated CD66c (REA414) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD66c. Human peripheral blood mononuclear cells (PBMCs) after erythrocyte lysis were stained with CD66c antibodies and with a suitable counterstaining. As a control, CD66c antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD66c. Human peripheral blood mononuclear cells (PBMCs) after erythrocyte lysis were stained with CD66c antibodies and with a suitable counterstaining. As a control, CD66c antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD66c. Human peripheral blood mononuclear cells (PBMCs) after erythrocyte lysis were stained with CD66c antibodies and with a suitable counterstaining. As a control, CD66c antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD66c. Human peripheral blood mononuclear cells (PBMCs) after erythrocyte lysis were stained with CD66c antibodies and with a suitable counterstaining. As a control, CD66c antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD66c. Human peripheral blood mononuclear cells (PBMCs) after erythrocyte lysis were stained with CD66c antibodies and with a suitable counterstaining. As a control, CD66c antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD66c (REA414). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD66c (REA414). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD66c (REA414). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD66c Antibody, anti-human, REAfinity™

Overview

Clone REA414 recognizes the human CD66c antigen, a glycosylphosphatidylinositol (GPI) linked protein, which is also known as carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6). Within the hematopoietic system, CD66c expression is limited to granulocytes and its precursors, where it serves homotypic and heterotypic adhesion, Ca
2+
mediated signaling, and is markedly upregulated from intracellular stores after activation. It is also found in epithelia of various organs. CD66c overexpression is found in a wide variety of epithelial cancer types such as lung, breast, colorectal, and hepatocellular carcinomas.
Additional information: Clone REA414 displays negligible binding to Fc receptors.

Alternative names

CEACAM6, CEAL, NCA, NCA-90

Detailed product information

Technical specifications

CloneREA414
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD66c
Alternative names of antigenCEACAM6, CEAL, NCA, NCA-90
Molecular mass of antigen [kDa]31
Distribution of antigenstem cells, granulocytes
Entrez Gene ID4680
RRIDAB_2752048, AB_2819479, AB_2819464, AB_2857814, AB_2857804, AB_2659001, AB_2659002, AB_2659003, AB_2659004, AB_2659005, AB_2659006, AB_2659007, AB_2659008, AB_2659009, AB_2659010, AB_2752061

Resources for CD66c Antibody, anti-human, REAfinity™

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD66c Antibody, anti-human, REAfinity™

Publications

  1. Neumaier, M. et al. (1988) Characterization of a cDNA clone for the nonspecific cross-reacting antigen (NCA) and a comparison of NCA and carcinoembryonic antigen. J. Biol. Chem. 263(7): 3202-3207
  2. Guillaume, N. et al. (2011) CD66c expression in B-cell acute lymphoblastic leukemia: strength and weakness. Int J Lab Hematol 33(1): 92-96
  3. Kiyokawa, N. et al. (2014) Significance of CD66c expression in childhood acute lymphoblastic leukemia. Leuk. Res. 38(1): 42-48

Related products for
CD66c Antibody, anti-human, REAfinity™

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?